Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

NCT05852717 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Large Cell Lymphoma, Diffuse
Relapsed Cancer
Refractory Cancer

Interventions

PROCEDURE: AutoSCT OR CAR T-cell Therapy
DRUG: GDP
DRUG: Epcoritamab

Sponsor

Dipenkumar Modi

Collaborators

[object Object]